A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-03-10
Adverse events
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-29 (study day 40); relationship: not assessed; serious criteria: hospitalization
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 91); relationship: N
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 106); relationship: not assessed
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-07 (study day 262); relationship: not assessed; serious criteria: hospitalization
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-19 (study day 336); relationship: N
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-03-11 (study day 357); relationship: N
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2024-06-08 (study day 446); relationship: not assessed
Data queries
No data queries.